ARS Pharmaceuticals is a technology company.
ARS Pharmaceuticals has raised $55.0M across 1 funding round.
ARS Pharmaceuticals has raised $55.0M in total across 1 funding round.
ARS Pharmaceuticals is a biopharmaceutical company, not a traditional technology company, focused on developing innovative treatments for allergic reactions.[1] Its lead product, neffy (previously ARS-1), is a needle-free nasal spray epinephrine designed as a potentially first-of-its-kind alternative to traditional auto-injectors like EpiPen for treating anaphylaxis.[1] The company serves patients with severe allergies, including those who struggle with needle-based delivery due to fear or usability issues, addressing the critical problem of rapid, accessible emergency treatment to prevent life-threatening reactions.[1]
Growth momentum has centered on advancing neffy through clinical development and regulatory milestones, positioning ARS Pharmaceuticals in the growing market for patient-friendly allergy therapies amid rising anaphylaxis cases.[1]
ARS Pharmaceuticals emerged in the biopharmaceutical space with a focus on proprietary delivery technologies for allergy treatments, though specific founding details like exact year or founders are not detailed in available profiles.[1][2] The company's idea stems from identifying gaps in current anaphylaxis treatments, leading to the development of neffy using novel ImmunoTAC technology for targeted immune modulation and needle-free administration.[2] Early traction likely built around neffy's potential as a disruptive product, gaining attention as a biotech innovator in allergy care.[1]
ARS Pharmaceuticals rides the trend of biotech advancements in drug delivery systems, particularly patient-centric innovations like needle-free alternatives amid increasing allergy prevalence driven by environmental and dietary factors.[1] Timing is favorable with regulatory interest in accessible epinephrine options and post-pandemic emphasis on home-based emergency care. Market forces include competition from legacy injectors and demand for easier-to-use devices, positioning the company to influence the allergy treatment ecosystem by expanding treatment adoption and potentially lowering barriers in underserved populations.[1][2]
Next steps likely involve neffy commercialization, FDA approvals, and partnerships to scale distribution, with trends like personalized medicine and digital health integrations shaping growth.[1] Influence may evolve by redefining anaphylaxis standards, boosting accessibility if neffy succeeds as a market leader—echoing its core mission to transform allergy emergency response from the ground up.[1][2]
ARS Pharmaceuticals has raised $55.0M in total across 1 funding round.
ARS Pharmaceuticals's investors include Endeavor Venture Funds, FPV Fund, Krishna Yeshwant, MPM Capital, Qiming Venture Partners USA, RA Capital, SR One, Westlake Village BioPartners.
ARS Pharmaceuticals has raised $55.0M across 1 funding round. Most recently, it raised $55.0M Series D in August 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2021 | $55.0M Series D | Endeavor Venture Funds, FPV Fund, Krishna Yeshwant, MPM Capital, Qiming Venture Partners USA, RA Capital, SR One, Westlake Village BioPartners |